We demonstrated that the elicited effect of CAR-T cells was target-specific, as CRISPR/Cas9-mediated disruption of HER2 abolished the sensitivity of melanoma cells to anti-HER2 CAR-T cells. The gene discussed is ERBB2; the disease is melanoma.